NeoPhore Limited, a cancer immuno-oncology company, announced yesterday that it has named Dr John Haurum as its new non-executive director with immediate effect.
Dr Haurum was earlier chief executive officer of F-star. Before F-star, he was VP Research at ImClone Systems, prior to this he was the CSO and Co-founder of Symphogen. He is currently executive chairman of the board at Synklino.
Robert James, chairman of NeoPhore, said, 'I would like to welcome John to the Neophore board. John has an excellent track record of building and growing companies in the biotech industry and his expertise and scientific understanding of the IO space will be invaluable as we maximise the potential of our platform.'
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories